Matthew A. Curry

Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)

Gregory R. Ott, Mangeng Cheng, Keith S. Learn et al. · Journal of Medicinal Chemistry · 2016 · 90 citations · Full text

Medicine, Oncology, Pharmacology +17

Non-Peptide Corticotropin-Releasing Hormone Antagonists:  Syntheses and Structure−Activity Relationships of 2-Anilinopyrimidines and -triazines

Argyrios G. Arvanitis, Paul J. Gilligan, Robert J. Chorvat et al. · Journal of Medicinal Chemistry · 1999 · 74 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Synthesis, Corticotropin-Releasing Factor Receptor Binding Affinity, and Pharmacokinetic Properties of Triazolo-, Imidazo-, and Pyrrolopyrimidines and -pyridines

Robert J. Chorvat, Rajagopal Bakthavatchalam, James P. Beck et al. · Journal of Medicinal Chemistry · 1999 · 63 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-<i>a</i>]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779

Benjamin J. Dugan, Diane E. Gingrich, Eugen F. Mesaros et al. · Journal of Medicinal Chemistry · 2012 · 62 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity

Gregory R. Ott, Rabindranath Tripathy, Mangeng Cheng et al. · ACS Medicinal Chemistry Letters · 2010 · 49 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +15